nach oben

Discover Oncology

Erschienen in:

03.02.2020

Progesterone and Breast Cancer: an NCI Workshop Report

verfasst von: Neeraja Sathyamoorthy, Carol A. Lange

Erschienen in: Discover Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Cathrin Brisken, cathrin.brisken@epfl.ch …

Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol. 2000;20(9):3102–15. doi: https://doi.org/10.1128/mcb.20.9.3102-3115.2000. PubMed PMID: 10757795; PMCID: PMC85605CrossRefPubMedPubMedCentral

Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang YF, Dembo AG, Schoenfelt K, Vadhi R, Qiu X, Rao P, Santhamma B, Nair HB, Nickisch KJ, Long HW, Becker L, Brown M, Greene GL. Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. Oncotarget. 2018;9(4):4282–300. doi: https://doi.org/10.18632/oncotarget.21378. PubMed PMID: 29435103; PMCID: PMC5796974

Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene. 2015;34(4):506–15. doi: https://doi.org/10.1038/onc.2013.579. PubMed PMID: 24469035; PMCID: PMC4112172CrossRefPubMedPubMedCentral

Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998;17(7):2008–18. doi: https://doi.org/10.1093/emboj/17.7.2008. PubMed PMID: 9524123; PMCID: PMC1170546CrossRefPubMedPubMedCentral

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015;523(7560):313–7. doi: https://doi.org/10.1038/nature14583. PubMed PMID: 26153859; PMCID: PMC4650274CrossRefPubMedPubMedCentral

Truong TH, Dwyer AR, Diep CH, Hu H, Hagen KM, Lange CA. Phosphorylated progesterone receptor isoforms mediate opposing stem cell and proliferative breast cancer cell fates. Endocrinology. 2019;160(2):430–46. doi: https://doi.org/10.1210/en.2018-00990. PubMed PMID: 30597041; PMCID: PMC6349004CrossRefPubMedCentral

Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL (1995) Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55(21):5063–5068PubMed

Bamberger AM, Milde-Langosch K, Schulte HM, Loning T (2000) Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 54(1):32–37. https://doi.org/10.1159/000063434 CrossRefPubMed

Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10(8):2751–2760. https://doi.org/10.1158/1078-0432.ccr-03-0141 CrossRefPubMed

10.

Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D, Forgez P, Byth K, Graham JD, Clarke CL (2015) Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. Breast Cancer Res Treat 151(2):309–318. https://doi.org/10.1007/s10549-015-3397-0 CrossRefPubMed

11.

Rojas PA, May M, Sequeira GR, Elia A, Alvarez M, Martinez P, Gonzalez P, Hewitt S, He X, Perou CM, Molinolo A, Gibbons L, Abba MC, Gass H, Lanari C. Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness. J Natl Cancer Inst. 2017;109(7). doi: https://doi.org/10.1093/jnci/djw317

12.

Daniel AR, Faivre EJ, Lange CA (2007) Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol 21(12):2890–2906. https://doi.org/10.1210/me.2007-0248 CrossRefPubMed

13.

Bonneterre J, Bosq J, Jamme P, Valent A, Gilles EM, Zukiwski AA, Fuqua SA, Lange CA, O’Shaughnessy J. Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open. 2016;1(4):e000072. doi: https://doi.org/10.1136/esmoopen-2016-000072. PubMed PMID: 27843626; PMCID: PMC5070234CrossRefPubMedPubMedCentral

14.

Mote PA, Bartow S, Tran N, Clarke CL (2002) Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 72(2):163–172. Epub 2002/06/01. https://doi.org/10.1023/a:1014820500738 CrossRefPubMed

15.

Mote PA, Johnston JF, Manninen T, Tuohimaa P, Clarke CL. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol. 2001;54(8):624–30. doi: https://doi.org/10.1136/jcp.54.8.624. PubMed PMID: 11477119; PMCID: PMC1731503CrossRefPubMedPubMedCentral

16.

Fabris V, Abascal MF, Giulianelli S, May M, Sequeira GR, Jacobsen B, Lombes M, Han J, Tran L, Molinolo A, Lanari C (2017) Isoform specificity of progesterone receptor antibodies. J Pathol Clin Res 3(4):227–233. https://doi.org/10.1002/cjp2.83 CrossRefPubMedPubMedCentral

17.

De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, Hunter DJ (2002) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A 99(19):12263–12268. https://doi.org/10.1073/pnas.192172299 CrossRefPubMedPubMedCentral

18.

Junqueira MG, da Silva ID, Nogueira-de-Souza NC, Carvalho CV, Leite DB, Gomes MT, Baracat EC, Lopes LA, Nicolau SM, Goncalves WJ (2007) Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development. Int J Gynecol Cancer 17(1):229–232. https://doi.org/10.1111/j.1525-1438.2006.00767.x CrossRefPubMed

19.

Liu T, Chen L, Sun X, Wang Y, Li S, Yin X, Wang X, Ding C, Li H, Di W (2014) Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies. Tumour Biol 35(3):2427–2436. https://doi.org/10.1007/s13277-013-1322-x CrossRefPubMed

20.

Govindan S, Ahmad SN, Vedicherla B, Kodati V, Jahan P, Rao KP, Ahuja YR, Hasan Q (2007) Association of progesterone receptor gene polymorphism (PROGINS) with endometriosis, uterine fibroids and breast cancer. Cancer Biomark 3(2):73–78. https://doi.org/10.3233/cbm-2007-3201 CrossRefPubMed

21.

Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB (1998) Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273(17):10696–10701. https://doi.org/10.1074/jbc.273.17.10696 CrossRefPubMed

22.

Agoulnik IU, Tong XW, Fischer DC, Korner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG (2004) A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 89(12):6340–6347. https://doi.org/10.1210/jc.2004-0114 CrossRefPubMed

23.

Lamb CA, Fabris VT, Jacobsen B, Molinolo AA, Lanari C (2018) Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer. Endocr Relat Cancer. https://doi.org/10.1530/ERC-18-0179 CrossRef

24.

Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S (2011) Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 17(12):4177–4186. https://doi.org/10.1158/1078-0432.CCR-10-2950 CrossRefPubMedPubMedCentral

25.

Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC (1994) Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 86(6):431–436. https://doi.org/10.1093/jnci/86.6.431 CrossRefPubMed

26.

Thomas CP, Liu KZ, Vats HS (2006) Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate alpha-ENaC and sgk1 expression in renal collecting duct epithelia. Am J Physiol Renal Physiol 290(2):F306–F312. https://doi.org/10.1152/ajprenal.00062.2005 CrossRefPubMed

27.

Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD (1999) Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 154(1–2):11–20. https://doi.org/10.1016/s0303-7207(99)00109-4 CrossRefPubMed

28.

Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR (2005) Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 97(4):328–341. https://doi.org/10.1016/j.jsbmb.2005.06.032 CrossRefPubMed

29.

Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E (2014) Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 124(2 Pt 1):292–299. https://doi.org/10.1097/AOG.0000000000000356 CrossRefPubMed

30.

Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O (2017) Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 377(23):2228–2239. https://doi.org/10.1056/NEJMoa1700732 CrossRefPubMed

31.

Africander DJ, Storbeck KH, Hapgood JP (2014) A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A). J Steroid Biochem Mol Biol 143:404–415. https://doi.org/10.1016/j.jsbmb.2014.05.007 CrossRefPubMed

32.

Louw-du Toit R, Perkins MS, Hapgood JP, Africander D (2017) Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy. Biochem Biophys Res Commun 491(1):140–146. https://doi.org/10.1016/j.bbrc.2017.07.063 CrossRefPubMedPubMedCentral

33.

Collaborative Group on Hormonal Factors in Breast C (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 394(10204):1159–1168. https://doi.org/10.1016/S0140-6736(19)31709-X CrossRef

34.

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Network TR, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 163(2):506–519. https://doi.org/10.1016/j.cell.2015.09.033 CrossRefPubMedPubMedCentral

35.

Tasdemir N, Bossart EA, Li Z, Zhu L, Sikora MJ, Levine KM, Jacobsen BM, Tseng GC, Davidson NE, Oesterreich S (2018) Comprehensive phenotypic characterization of human invasive lobular carcinoma cell lines in 2D and 3D cultures. Cancer Res 78(21):6209–6222. https://doi.org/10.1158/0008-5472.CAN-18-1416 CrossRefPubMedPubMedCentral

36.

Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirstrom K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep. 2016;6:18517. doi: https://doi.org/10.1038/srep18517

37.

Dossus L, Benusiglio PR (2015) Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 17:37. https://doi.org/10.1186/s13058-015-0546-7 CrossRefPubMedPubMedCentral

38.

Harrell JC, Shroka TM, Jacobsen BM (2017) Estrogen induces c-kit and an aggressive phenotype in a model of invasive lobular breast cancer. Oncogenesis. 6(11):396. https://doi.org/10.1038/s41389-017-0002-x CrossRefPubMedPubMedCentral

39.

Matthews SB, Sartorius CA (2017) Steroid hormone receptor positive breast cancer patient-derived xenografts. Horm Cancer 8(1):4–15. https://doi.org/10.1007/s12672-016-0275-0 CrossRefPubMed

40.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016;35(4):547–73. doi: https://doi.org/10.1007/s10555-016-9653-x CrossRefPubMed

41.

Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA (2017) Breast cancer suppression by progesterone receptors is mediated by their modulation of estrogen receptors and RNA polymerase III. Cancer Res 77(18):4934–4946. https://doi.org/10.1158/0008-5472.CAN-16-3541 CrossRefPubMedPubMedCentral

42.

Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, Raffoul W, Delaloye JF, Treboux A, Fiche M, Vilo J, Ayyanan A, Brisken C (2016) A preclinical model for ERalpha-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell 29(3):407–422. https://doi.org/10.1016/j.ccell.2016.02.002 CrossRefPubMed

43.

Fiche M, Scabia V, Aouad P, Battista L, Treboux A, Stravodimou A, Zaman K (2019) Rls, Dormoy V, Ayyanan a, Sflomos G, Brisken C. Intraductal patient-derived xenografts of estrogen receptor alpha-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions. J Pathol 247(3):287–292. https://doi.org/10.1002/path.5200 CrossRefPubMed

44.

Knutson TP, Lange CA (2014) Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther 142(1):114–125. https://doi.org/10.1016/j.pharmthera.2013.11.010 CrossRefPubMed

45.

Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C. Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med. 2013;5(182):182ra55. doi: https://doi.org/10.1126/scitranslmed.3005654 CrossRefPubMed

46.

Rajaram RD, Buric D, Caikovski M, Ayyanan A, Rougemont J, Shan J, Vainio SJ, Yalcin-Ozuysal O, Brisken C. Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk. EMBO J. 2015;34(5):641–52. doi: https://doi.org/10.15252/embj.201490434 CrossRefPubMedPubMedCentral

47.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 468(7320):98–102. https://doi.org/10.1038/nature09387 CrossRefPubMedPubMedCentral

48.

Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R (2010) Progesterone induces adult mammary stem cell expansion. Nature. 465(7299):803–807. https://doi.org/10.1038/nature09091 CrossRefPubMed

49.

Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107(1):103–111. https://doi.org/10.1007/s10549-007-9523-x CrossRefPubMed

50.

Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, Menon U, Jacobs IJ (2013) The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol 14(12):1226–1232. https://doi.org/10.1016/S1470-2045(13)70448-0 CrossRefPubMed

51.

Kim J, Oktay K (2013) Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes Control 24(3):421–426. https://doi.org/10.1007/s10552-012-0127-3 CrossRefPubMed

52.

Goodman ML, Trinca GM, Walter KR, Papachristou EK, D'Santos CS, Li T, Liu Q, Lai Z, Chalise P, Madan R, Fan F, Markiewicz MA, Jin VX, Carroll JS, Hagan CR (2019) Progesterone receptor attenuates STAT1-mediated IFN signaling in breast cancer. J Immunol 202(10):3076–3086. https://doi.org/10.4049/jimmunol.1801152 CrossRefPubMed

53.

Presman DM, Ogara MF, Stortz M, Alvarez LD, Pooley JR, Schiltz RL, Grontved L, Johnson TA, Mittelstadt PR, Ashwell JD, Ganesan S, Burton G, Levi V, Hager GL, Pecci A (2014) Live cell imaging unveils multiple domain requirements for in vivo dimerization of the glucocorticoid receptor. PLoS Biol 12(3):e1001813. https://doi.org/10.1371/journal.pbio.1001813 CrossRefPubMedPubMedCentral

54.

Presman DM, Ganguly S, Schiltz RL, Johnson TA, Karpova TS, Hager GL (2016) DNA binding triggers tetramerization of the glucocorticoid receptor in live cells. Proc Natl Acad Sci U S A 113(29):8236–8241. https://doi.org/10.1073/pnas.1606774113 CrossRefPubMedPubMedCentral

55.

Paakinaho V, Johnson TA, Presman DM, Hager GL (2019) Glucocorticoid receptor quaternary structure drives chromatin occupancy and transcriptional outcome. Genome Res 29(8):1223–1234. https://doi.org/10.1101/gr.244814.118 CrossRefPubMedPubMedCentral

56.

Xiao S, Coppeta JR, Rogers HB, Isenberg BC, Zhu J, Olalekan SA, McKinnon KE, Dokic D, Rashedi AS, Haisenleder DJ, Malpani SS, Arnold-Murray CA, Chen K, Jiang M, Bai L, Nguyen CT, Zhang J, Laronda MM, Hope TJ, Maniar KP, Pavone ME, Avram MJ, Sefton EC, Getsios S, Burdette JE, Kim JJ, Borenstein JT, Woodruff TK (2017) A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle. Nat Commun 8:14584. https://doi.org/10.1038/ncomms14584 CrossRefPubMedPubMedCentral

57.

Villanueva H, Grimm S, Dhamne S, Rajapakshe K, Visbal A, Davis CM, Ehli EA, Hartig SM, Coarfa C, Edwards DP (2018) The emerging roles of steroid hormone receptors in ductal carcinoma in situ (DCIS) of the breast. J Mammary Gland Biol Neoplasia 23(4):237–248. https://doi.org/10.1007/s10911-018-9416-0 CrossRefPubMedPubMedCentral

58.

Elsarraj HS, Valdez KE, Hong Y, Grimm SL, Ricci LR, Fan F, Tawfik O, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Winblad O, Hilsenbeck S, Edwards DP, Hagan CR, Godwin AK, Fabian C, Behbod F (2017) NEMO, a transcriptional target of estrogen and progesterone, is linked to tumor suppressor PML in breast cancer. Cancer Res 77(14):3802–3813. https://doi.org/10.1158/0008-5472.CAN-16-2794 CrossRefPubMedPubMedCentral

59.

Valdez KE, Fan F, Smith W, Allred DC, Medina D, Behbod F (2011) Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol 225(4):565–573. https://doi.org/10.1002/path.2969 CrossRefPubMedPubMedCentral

60.

Janzen DM, Rosales MA, Paik DY, Lee DS, Smith DA, Witte ON, Iruela-Arispe ML, Memarzadeh S (2013) Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res 73(15):4697–4710. https://doi.org/10.1158/0008-5472.CAN-13-0930 CrossRefPubMedPubMedCentral

61.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. doi: https://doi.org/10.1001/jama.288.3.321

62.

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, Investigators WHI (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 304(15):1684–1692. https://doi.org/10.1001/jama.2010.1500 CrossRefPubMedPubMedCentral

63.

Beral V, Million Women Study C. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427. doi: https://doi.org/10.1016/s0140-6736(03)14065-2

64.

Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the postmenopausal estrogen/progestin interventions mammographic density study. Am J Epidemiol 162(9):826–834. https://doi.org/10.1093/aje/kwi286 CrossRefPubMed

65.

Moyer DL, Felix JC, Kurman RJ, Cuffie CA (2001) Micronized progesterone regulation of the endometrial glandular cycling pool. Int J Gynecol Pathol 20(4):374–379. https://doi.org/10.1097/00004347-200110000-00010 CrossRefPubMed

66.

Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI (1983) Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J (Clin Res Ed) 287(6401):1241–1245. https://doi.org/10.1136/bmj.287.6401.1241 CrossRef

67.

Fournier A, Dossus L, Mesrine S, Vilier A, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N (2014) Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol 180(5):508–517. https://doi.org/10.1093/aje/kwu146 CrossRefPubMed

68.

Casey AE, Sinha A, Singhania R, Livingstone J, Waterhouse P, Tharmapalan P, Cruickshank J, Shehata M, Drysdale E, Fang H, Kim H, Isserlin R, Bailey S, Medina T, Deblois G, Shiah YJ, Barsyte-Lovejoy D, Hofer S, Bader G, Lupien M, Arrowsmith C, Knapp S, De Carvalho D, Berman H, Boutros PC, Kislinger T, Khokha R (2018) Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. J Cell Biol 217(8):2951–2974. https://doi.org/10.1083/jcb.201804042 CrossRefPubMedPubMedCentral

Titel: Progesterone and Breast Cancer: an NCI Workshop Report
verfasst von: Neeraja Sathyamoorthy
Carol A. Lange
Publikationsdatum: 03.02.2020
Verlag: Springer US
Erschienen in: Discover Oncology / Ausgabe 1/2020
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-020-00379-1

Springer Medizin

Progesterone and Breast Cancer: an NCI Workshop Report

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis

Molecular and Electrophysiological Analyses of ATP2B4 Gene Variants in Bilateral Adrenal Hyperaldosteronism

Platelet ATP, Thyroid Hormone Receptor on Integrin αvβ3 and Cancer Metastasis

The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer

A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie